-
Je něco špatně v tomto záznamu ?
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment
L. Zemanova, J. Hofman, E. Novotna, K. Musilek, T. Lundova, J. Havrankova, A. Hostalkova, J. Chlebek, L. Cahlikova, V. Wsol,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- aldehydreduktasa antagonisté a inhibitory účinky léků MeSH
- apigenin farmakologie MeSH
- daunomycin farmakologie MeSH
- flavonoidy farmakologie MeSH
- flavony chemie farmakologie MeSH
- HCT116 buňky MeSH
- inhibitory enzymů chemie MeSH
- lidé MeSH
- luteolin farmakologie MeSH
- molekulární konformace MeSH
- molekulární struktura MeSH
- nádory farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
AKR1B10 is an NADPH-dependent reductase that plays an important function in several physiological reactions such as the conversion of retinal to retinol, reduction of isoprenyl aldehydes, and biotransformation of procarcinogens and drugs. A growing body of evidence points to the important role of the enzyme in the development of several types of cancer (e.g., breast, hepatocellular), in which it is highly overexpressed. AKR1B10 is regarded as a therapeutic target for the treatment of these diseases, and potent and specific inhibitors may be promising therapeutic agents. Several inhibitors of AKR1B10 have been described, but the area of natural plant products has been investigated sparingly. In the present study almost 40 diverse phenolic compounds and alkaloids were examined for their ability to inhibit the recombinant AKR1B10 enzyme. The most potent inhibitors-apigenin, luteolin, and 7-hydroxyflavone-were further characterized in terms of IC50, selectivity, and mode of action. Molecular docking studies were also conducted, which identified putative binding residues important for the interaction. In addition, cellular studies demonstrated a significant inhibition of the AKR1B10-mediated reduction of daunorubicin in intact cells by these inhibitors without a considerable cytotoxic effect. Although these compounds are moderately potent and selective inhibitors of AKR1B10, they constitute a new structural type of AKR1B10 inhibitor and may serve as a template for the development of better inhibitors.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16009916
- 003
- CZ-PrNML
- 005
- 20160415101029.0
- 007
- ta
- 008
- 160408s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jnatprod.5b00616 $2 doi
- 024 7_
- $a 10.1021/acs.jnatprod.5b00616 $2 doi
- 035 __
- $a (PubMed)26529431
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Zemanova, Lucie
- 245 10
- $a Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment / $c L. Zemanova, J. Hofman, E. Novotna, K. Musilek, T. Lundova, J. Havrankova, A. Hostalkova, J. Chlebek, L. Cahlikova, V. Wsol,
- 520 9_
- $a AKR1B10 is an NADPH-dependent reductase that plays an important function in several physiological reactions such as the conversion of retinal to retinol, reduction of isoprenyl aldehydes, and biotransformation of procarcinogens and drugs. A growing body of evidence points to the important role of the enzyme in the development of several types of cancer (e.g., breast, hepatocellular), in which it is highly overexpressed. AKR1B10 is regarded as a therapeutic target for the treatment of these diseases, and potent and specific inhibitors may be promising therapeutic agents. Several inhibitors of AKR1B10 have been described, but the area of natural plant products has been investigated sparingly. In the present study almost 40 diverse phenolic compounds and alkaloids were examined for their ability to inhibit the recombinant AKR1B10 enzyme. The most potent inhibitors-apigenin, luteolin, and 7-hydroxyflavone-were further characterized in terms of IC50, selectivity, and mode of action. Molecular docking studies were also conducted, which identified putative binding residues important for the interaction. In addition, cellular studies demonstrated a significant inhibition of the AKR1B10-mediated reduction of daunorubicin in intact cells by these inhibitors without a considerable cytotoxic effect. Although these compounds are moderately potent and selective inhibitors of AKR1B10, they constitute a new structural type of AKR1B10 inhibitor and may serve as a template for the development of better inhibitors.
- 650 _2
- $a aldehydreduktasa $x antagonisté a inhibitory $x účinky léků $7 D000449
- 650 _2
- $a apigenin $x farmakologie $7 D047310
- 650 _2
- $a daunomycin $x farmakologie $7 D003630
- 650 _2
- $a inhibitory enzymů $x chemie $7 D004791
- 650 _2
- $a flavony $x chemie $x farmakologie $7 D047309
- 650 _2
- $a flavonoidy $x farmakologie $7 D005419
- 650 _2
- $a HCT116 buňky $7 D045325
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a luteolin $x farmakologie $7 D047311
- 650 _2
- $a molekulární konformace $7 D008968
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a nádory $x farmakoterapie $7 D009369
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hofman, Jakub
- 700 1_
- $a Novotna, Eva
- 700 1_
- $a Musilek, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove , Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic.
- 700 1_
- $a Lundova, Tereza
- 700 1_
- $a Havrankova, Jana
- 700 1_
- $a Hostalkova, Anna
- 700 1_
- $a Chlebek, Jakub
- 700 1_
- $a Cahlikova, Lucie
- 700 1_
- $a Wsol, Vladimír
- 773 0_
- $w MED00010055 $t Journal of natural products $x 1520-6025 $g Roč. 78, č. 11 (2015), s. 2666-74
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26529431 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160415101114 $b ABA008
- 999 __
- $a ok $b bmc $g 1113345 $s 934284
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 78 $c 11 $d 2666-74 $e 20151103 $i 1520-6025 $m Journal of natural products $n J Nat Prod $x MED00010055
- LZP __
- $a Pubmed-20160408